PRESS RELEASE published on 05/28/2024 at 19:00, 2 years 3 months ago JTC Team to Host the Virtual Investor Pitch Conference on June 17-18, 2024 JTC Team announces Virtual Investor Pitch Conference on June 17-18, 2024, featuring live video webcast presentations with Q&A. Participating company line-up to be revealed later Investor Relations JTC Team Virtual Investor Pitch Conference Live Video Webcast Q&A
BRIEF published on 05/23/2024 at 16:35, 2 years 3 months ago GRI Bio (NASDAQ : GRI) participe à Virtual Investor CEO Connect Relations Avec Les Investisseurs Communications D'entreprise Biographie Du GRI Investisseur Virtuel Connexion Du PDG
BRIEF published on 05/23/2024 at 16:35, 2 years 3 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect Investor Relations Corporate Communications GRI Bio Virtual Investor CEO Connect
PRESS RELEASE published on 05/23/2024 at 16:30, 2 years 3 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect JTC Team announces CEO Connect segment with GRI Bio's Marc Hertz, PhD, covering recent achievements and upcoming milestones. Virtual Investor platform offers more videos GRI Bio Virtual Investor CEO Connect JTC Team Communication Strategies
BRIEF published on 04/25/2024 at 15:50, 2 years 4 months ago Moleculin Biotech souligne le rôle de l'annamycine dans le traitement de la LMA dans le segment des investisseurs virtuels du JTC Essais Cliniques Opportunité D'investissement Biotechnologie Moléculaire Annamycine Traitement LMA
BRIEF published on 04/25/2024 at 15:50, 2 years 4 months ago Moleculin Biotech Emphasizes Annamycin's Role in AML Treatment in JTC Virtual Investor Segment Clinical Trials Investment Opportunity Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 04/25/2024 at 15:45, 2 years 4 months ago Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team Moleculin CEO highlights Annamycin's differentiation in AML treatment landscape and investment opportunity. Positive interim data shared in 'What This Means' segment Investment Opportunity Clinical Trial Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 10/18/2023 at 16:00, 2 years 10 months ago JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023
Published on 09/12/2026 at 02:35, 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 3 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 4 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 5 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 9 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 22:15, 4 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 4 hours 30 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 6 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 8 hours 25 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 19 hours 41 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 19 hours 41 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 19 hours 41 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 19 hours 41 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 7 hours ago Availability of the 2026 Interim Financial Report
